• Explore how AI models decode complex disease biology by identifying pathological features, mapping dysregulated pathways, and pinpointing high-confidence drug targets at a systems level.
• Learn how foundational and generative models accelerate de novo therapeutic discovery by predicting target–disease associations and streamlining early development decisions.

Casandra Mangroo

Ari Allyn-Feuer

Arvind Rao
BenchiSci
Website: https://www.benchsci.com/
BenchSci is a world leader in AI software for biopharma research and development on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. For more information about BenchSci, visit www.benchsci.com.





